Patents Assigned to DAFRA PHARMA N.V.
  • Pharmaceutical carrier composition and pharmaceutical composition
    Patent number: 8937085
    Abstract: The present invention relates to a pharmaceutical carrier composition and a pharmaceutical composition comprising said pharmaceutical carrier composition. The pharmaceutical composition comprises: (a) at least 20% (w/w) of the composition of a sugar or a sugar alcohol; (b) one or more pharmaceutically acceptable excipients; (c) one or more pharmaceutically active ingredients in their base form; and (d) water up to 100% (w/w). The present pharmaceutical composition is especially resistant against flocculation, clumping and/or precipitation at room temperature during prolonged time-periods such as one or more years.
    Type: Grant
    Filed: February 13, 2008
    Date of Patent: January 20, 2015
    Assignee: Dafra Pharma N.V.
    Inventor: Frans Herwig Jansen
  • Increasing the in vivo biological activity of biologically active compounds
    Patent number: 8692003
    Abstract: The present invention relates to compounds with an increased in vivo biological activity, and especially an increased pharmaceutical activity, such as an anti-nematodal or antifungal activity, an immunosuppresive activity, a metabolism influencing activity and/or an anti-cancer activity. Specifically, the present invention relates to compound comprising an artemisinin derivative according to the general formula (I) covalently linked at the 1 or the 2 position to a compound with a biological activity thereby increasing the biological activity of said compound or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: April 8, 2014
    Assignee: Dafra Pharma N.V.
    Inventors: Frans Herwig Jansen, Shahid Ahmed Soomro
  • Artemisinin-Like Derivatives with Cytotoxic and Anti-Angiogenic Properties
    Publication number: 20130296412
    Abstract: The present invention relates to novel artemisinin-like derivates, and especially dihydroartemisinin derivates and pharmaceutical compositions comprising the present compounds. The present invention further relates to the use of the present compounds for the treatment of cancer, especially by oral administration. Especially, the present invention relates to dihydroartemisinin compounds (DHA) substituted by, through an ester linkage by a linear or branched C1 to C6 alkyl optionally substituted by one or more halogens. Especially preferred substituents are acetate, propionate, isopropionate, butyrate and isobutyrate.
    Type: Application
    Filed: August 3, 2011
    Publication date: November 7, 2013
    Applicant: DAFRA PHARMA N.V.
    Inventor: Frans Herwig Jansen
  • Increasing the In Vivo Biological Activity of Biologically Active Compounds
    Publication number: 20100286393
    Abstract: The present invention relates to compounds with an increased in vivo biological activity, and especially an increased pharmaceutical activity, such as an anti-nematodal or antifungal activity, an immunosuppresive activity, a metabolism influencing activity and/or an anti-cancer activity. Specifically, the present invention relates to compound comprising an artemisinin derivative according to the general formula (I) covalently linked at the 1 or the 2 position to a compound with a biological activity thereby increasing the biological activity of said compound or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 10, 2008
    Publication date: November 11, 2010
    Applicant: DAFRA PHARMA N.V.
    Inventors: Frans Herwing Jansen, Shahid Ahmed Soomro